Conditions: Adenocarcinoma
Keywords: Adenocarcinoma Gastroesophageal Junction
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.

Detailed description:

Arms:
arm 1: Each treatment cycle is 4 weeks (28 days)

Interventions: intervention 1: Ramucirumab (IMC-1121B ) intervention 2: Paclitaxel
Intervention descriptions: intervention 1: 8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle intervention 2: 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle

Protocol document: